• Evangelos Tsipotis, Ankith Maremanda, Laura Bowles Zeiser, Caoilfhionn Connolly, Sowmya Sharma, Sharon Dudley-Brown, Sarah Frey, Mark Lazarev, Joanna M Melia, Alyssa M Parian, Dorry L Segev, Brindusa Truta, Huimin Yu, William A Werbel, and Florin M Selaru.
• Digestive Health Center, Augusta University, Augusta, GA 30912, USA.
• Medicina (Kaunas). 2023 Aug 18; 59 (8).

AbstractBackground: The emergence of new SARS-CoV-2 variants calls for more data on SARS-CoV-2 mRNA vaccine response. Aims: We aimed to assess the response to a third mRNA vaccine dose against SARS-CoV-2 in inflammatory bowel disease (IBD) patients. Methods: This was a single-center, observational prospective study of IBD patients who received a third mRNA vaccine dose against SARS-CoV-2. Antibody titers were taken post-third-dose at one and three months using the Roche Elecsys anti-SARS-CoV-2-S enzyme immunoassay. Titers less than 0.8 units/mL were considered negative according to the manufactures. Titers between 0.8 units/mL and 250 units/mL were considered non-neutralizing. Titers greater than 250 units/mL were considered neutralizing. Results: Eighty-three patients were included, all of whom had detectable antibodies at 3 months post-third dose. A total of 89% showed neutralizing and 11% non-neutralizing titers. Participants with non-neutralizing titers were more likely to be on systemic corticosteroids (p = 0.04). Two participants seroconverted from negative to positive, whereas 86% with non-neutralizing titers boosted to neutralizing levels. Only one participant with neutralizing titers after a third dose had a decrease to a non-neutralizing level within 3 months. Conclusions: Our findings support the ongoing recommendations for additional doses in immunocompromised individuals. However, longitudinal studies with a greater-sized patient population are needed.

16 keywords...

hide…